Immunoprecise Antibodies Ltd (IPA) — Cash Flow-to-Debt Ratio
Immunoprecise Antibodies Ltd (IPA) has a Cash Flow-to-Debt Ratio of -0.05x as of April 2025, meaning its operating cash flow of $-1.14 Million could theoretically repay 0% of its total liabilities ($20.82 Million) in one year. Explore investment intensity of Immunoprecise Antibodies Ltd to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Immunoprecise Antibodies Ltd Cash Flow-to-Debt Ratio (1997–2025)
Historical debt coverage capacity for Immunoprecise Antibodies Ltd across 29 annual periods. Also explore Immunoprecise Antibodies Ltd total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Immunoprecise Antibodies Ltd (1997–2025)
Year-by-year debt coverage analysis for Immunoprecise Antibodies Ltd. For market capitalisation and broader financial context, see market value of Immunoprecise Antibodies Ltd.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.31x | $-6.41 Million | $20.82 Million | ▼ -89.1% |
| 2024 | -0.16x | $-4.25 Million | $26.07 Million | ▲ +83.6% |
| 2023 | -0.99x | $-19.83 Million | $20.01 Million | ▼ -81.9% |
| 2022 | -0.54x | $-9.92 Million | $18.21 Million | ▼ -811.2% |
| 2021 | -0.06x | $-600.00K | $10.04 Million | ▲ +47.7% |
| 2020 | -0.11x | $-1.39 Million | $12.18 Million | ▲ +63.4% |
| 2019 | -0.31x | $-3.21 Million | $10.28 Million | ▼ -8.4% |
| 2018 | -0.29x | $-3.42 Million | $11.87 Million | ▲ +66.6% |
| 2017 | -0.86x | $-721.65K | $836.91K | ▼ -243.3% |
| 2016 | 0.60x | $284.09K | $472.15K | ▲ +524.3% |
| 2015 | -0.14x | $-36.11K | $254.64K | ▲ +7.7% |
| 2014 | -0.15x | $-46.60K | $303.50K | ▼ -840.9% |
| 2013 | -0.02x | $-4.33K | $265.63K | ▲ +97.4% |
| 2012 | -0.62x | $-132.72K | $213.10K | ▲ +14.6% |
| 2011 | -0.73x | $-80.39K | $110.21K | ▲ +76.9% |
| 2010 | -3.15x | $-308.49K | $97.87K | ▼ -205.4% |
| 2009 | -1.03x | $-155.68K | $150.84K | ▲ +92.6% |
| 2008 | -13.97x | $-523.45K | $37.46K | ▼ -1844.4% |
| 2007 | -0.72x | $-297.31K | $413.69K | ▲ +9.9% |
| 2006 | -0.80x | $-110.59K | $138.62K | ▲ +54.2% |
| 2005 | -1.74x | $-82.20K | $47.18K | ▲ +51.3% |
| 2004 | -3.58x | $-178.69K | $49.92K | ▲ +37.2% |
| 2003 | -5.70x | $-168.38K | $29.53K | ▼ -281.9% |
| 2002 | -1.49x | $-280.23K | $187.72K | ▼ -16357.5% |
| 2001 | -0.01x | $-8.13K | $896.75K | ▲ +100.0% |
| 2000 | -20.63x | $-208.54K | $10.11K | ▼ -263.7% |
| 1999 | -5.67x | $-202.94K | $35.78K | ▼ -68.5% |
| 1998 | -3.37x | $-226.81K | $67.39K | ▼ -677.8% |
| 1997 | -0.43x | $-108.20K | $250.04K | — |